Galantamine may improve attention and speech in schizophrenia

Human Psychopharmacology

Volumn 21, Issue 2, 2006, Pages 127-128

  Ochoa, Enrique L M ^a   Clark, Elizabeth ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DONEPEZIL; GALANTAMINE; OLANZAPINE; RISPERIDONE; VALPROATE SEMISODIUM;

ANHEDONIA; APATHY; ATTENTION DISTURBANCE; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; HUMAN; LETTER; NEGATIVE SYNDROME; PRIORITY JOURNAL; SCHIZOPHRENIA; SPEECH DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ATTENTION; BENZODIAZEPINES; CHOLINESTERASE INHIBITORS; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SPEECH;

EID: 33644620920     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.751     Document Type: Letter

References (13)

1. Allen TB, McEvoy JP. 2002. Galantamine for treatment-resistant schizophrenia. Am J Psychiatry 159: 1244-1245.
2. Arnold DS, Rosse RB, Dickinson D, Benham R, Deutsch SI, Nelson MW. 2004. Adjuvant Therapeutic Effects of Galantamine on Apathy in a Schizophrenia Patient. J Clin Psychiatry 65: 1723-1724.
3. Buchanan RW, Summerfelt A, Tek C, Gold J. 2003. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59: 29-33.
4. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. 1992. A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41: 31-37.
5. Levin ED, McClernon FJ, Rezvani AH. 2005. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl): 1-17.
6. Maelicke A, Albuquerque EX. 2000. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. European Journal of Pharmacology 393: 165-170.
7. O'Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC. 2000. Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 12: 4-15.
8. Purdon SE. 2005. (Personal Communication).
9. Rosse RB, Deutsch SI. 2002. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 25: 272-275.
10. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the galantamine USA- 10 study group. Neurology 54: 2269-2276.
11. Vibat CR, Lasalde JA, McNamee MG, Ochoa EL. 1995. Differential desensitization properties of rat neuronal nicotinic acetylcholinereceptor subunit combinations expressed in Xenopus laevis oocytes. Cellular and Molecular Neurobiology 15: 411-425.
12. Wilcock GK, Lilienfeld S, Gaens E. 2000a. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Brit Med J 321: 1445-1449.
13. Wilcock GK, Lifienfeld S, Gaens E. 2000b. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Bmj 321: 1445-1449.